<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36186977</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>The rationale for the treatment of long-Covid symptoms - A cardiologist's view.</ArticleTitle><Pagination><StartPage>992686</StartPage><MedlinePgn>992686</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">992686</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2022.992686</ELocationID><Abstract><AbstractText>The ongoing coronavirus disease 2019 pandemic left us with thousands of patients suffering from neurological, cardiovascular, and psychiatric disorders named post-acute sequelae of COVID-19 or just <i>long-Covid</i>. In parallel, the vaccination campaigns against SARS-CoV-2 spike protein saved millions of lives worldwide but long-Covid symptoms also appeared rarely following vaccination with a strong overlap to the "canonical" long-Covid symptoms. A therapeutic strategy targeting both, post-VAC and post-SARS-CoV-2 long-Covid symptoms is warranted since exposure to the S-protein either by vaccination or SARS-CoV-2 infection may trigger identical immuno-inflammatory cascades resulting in long-Covid symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Schieffer and Schieffer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schieffer</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Critical Care Medicine, University Hospital Marburg (UKGM), Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schieffer</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Critical Care Medicine, University Hospital Marburg (UKGM), Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Cardiovasc Med. 2023 Jul 21;10:1244340. doi: 10.3389/fcvm.2023.1244340</RefSource><PMID Version="1">37547250</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HDL - cholesterol</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">histamin challenge</Keyword><Keyword MajorTopicYN="N">kalkrein-kinin system</Keyword><Keyword MajorTopicYN="N">lipid &#x2013; hybrid nanoparticles</Keyword><Keyword MajorTopicYN="N">long-Covid syndrome</Keyword><Keyword MajorTopicYN="N">renin-angiotensin system</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36186977</ArticleId><ArticleId IdType="pmc">PMC9520195</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.992686</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A. A adverse effects of COVID-19 mRNA vaccines: the spike hypothesis Trends. Mol Med Juli. (2022) 28:542&#x2013;54. 10.1016/j.molmed.2022.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.04.007</ArticleId><ArticleId IdType="pmc">PMC9021367</ArticleId><ArticleId IdType="pubmed">35537987</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO.Int . Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.</Citation></Reference><Reference><Citation>WHO COVID-19 vaccine . Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. (2020) 383:2603&#x2013;15. 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2021) 384:403&#x2013;16. 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci Februar. (2021) 25:1663&#x2013;9. 10.26355/eurrev_202102_24877</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202102_24877</ArticleId><ArticleId IdType="pubmed">33629336</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci Januar. (2022) 43:3&#x2013;40. 10.1007/s10072-021-05662-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05662-9</ArticleId><ArticleId IdType="pmc">PMC8557950</ArticleId><ArticleId IdType="pubmed">34719776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. (2022) 165:386&#x2013;401. 10.1111/imm.13443</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. (2022) 25:16. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. (2022) 13:3528. 10.1101/2021.06.24.21259277</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.24.21259277</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M. Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis Off Publ Infect Dis Soc Am. (2022) 1:715&#x2013;8. 10.1093/cid/ciab465</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab465</ArticleId><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, Bullock TA, McGary HM, Khan JA. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis. (2020) 146:105131. 10.1016/j.nbd.2020.105131</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105131</ArticleId><ArticleId IdType="pmc">PMC7547916</ArticleId><ArticleId IdType="pubmed">33053430</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy WJ, Longo DL. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. N Engl J Med. (2022) 386:394&#x2013;6. 10.1056/NEJMcibr2113694</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr2113694</ArticleId><ArticleId IdType="pubmed">34818473</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo &#xc2;, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J. Fc&#x3b3;R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. (2022) 606:576&#x2013;84. 10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuya K, Hattori T, Saito T, Takadate Y, Sasaki M, Furuyama W. u. a. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. Microbiol Spectr. (2022) 23:e0155321. 10.1128/spectrum.01553-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01553-21</ArticleId><ArticleId IdType="pmc">PMC9045191</ArticleId><ArticleId IdType="pubmed">35319248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, Valenzuela R, Suarez-Quintanilla JA, Cortes-Ayaso M. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. (2021) 122:102683. 10.1016/j.jaut.2021.102683</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102683</ArticleId><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. (2021) 4:100100. 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Papola F, Biancofiore V, Angeletti C, Grimaldi A, Carucci AC, Cofini V. Anti-AT1R autoantibodies and prediction of the severity of COVID-19. Hum Immunol. (2022) 83:130&#x2013;3. 10.1016/j.humimm.2021.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8577881</ArticleId><ArticleId IdType="pubmed">34772541</ArticleId></ArticleIdList></Reference><Reference><Citation>Let's talk about lipid nanoparticles. Nat Rev Mater. (2021) 6:99. 10.1038/s41578-021-00281-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00281-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis Mai. (2022) 28:657&#x2013;66. 10.1016/j.cmi.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieffer E, Schieffer B. The Race for ACE: targeting angiotensin-converting enzymes (ACE) in SARS-CoV-2 infection. Li X, Herausgeber J Renin Angiotensin Aldosterone Syst. (2022) 2022:1&#x2013;6. 10.1155/2022/2549063</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2549063</ArticleId><ArticleId IdType="pmc">PMC9166989</ArticleId><ArticleId IdType="pubmed">35685188</ArticleId></ArticleIdList></Reference><Reference><Citation>Colafella KMM, Hilliard LM, Denton KM. Epochs in the depressor/pressor balance of the renin-angiotensin system. Clin Sci Lond Engl. (2016) 130:761&#x2013;71. 10.1042/CS20150939</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20150939</ArticleId><ArticleId IdType="pubmed">27128801</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother Biomedecine Pharmacother. (2017) 94:317&#x2013;25. 10.1016/j.biopha.2017.07.091</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.07.091</ArticleId><ArticleId IdType="pubmed">28772209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabassum A, Iqbal MS, Sultan S, Alhuthali RA, Alshubaili DI, Sayyam RS. Dysregulated Bradykinin: mystery in the pathogenesis of COVID-19 mediators. Inflammation. (2022) 2022:7423537. 10.1155/2022/7423537</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7423537</ArticleId><ArticleId IdType="pmc">PMC8826266</ArticleId><ArticleId IdType="pubmed">35153624</ArticleId></ArticleIdList></Reference><Reference><Citation>Raidoo DM, Bhoola KD. Kinin receptors on human neurones. J Neuroimmunol Juli. (1997) 77:39&#x2013;44. 10.1016/S0165-5728(97)00048-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(97)00048-9</ArticleId><ArticleId IdType="pubmed">9209266</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife. (2020) 9:e59177. 10.7554/eLife.59177</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59177</ArticleId><ArticleId IdType="pmc">PMC7410499</ArticleId><ArticleId IdType="pubmed">32633718</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Du Y, Ding H, Haque A, Hicks J, Pedroza C. Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis. Arthritis Res Ther. (2019) 21:12. 10.1186/s13075-018-1774-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1774-x</ArticleId><ArticleId IdType="pmc">PMC6325757</ArticleId><ArticleId IdType="pubmed">30621761</ArticleId></ArticleIdList></Reference><Reference><Citation>Parekh RU, Sriramula S. Activation of Kinin B1R upregulates ADAM17 and results in ACE2 shedding in neurons. Int J Mol Sci. (2020) 22:145. 10.3390/ijms22010145</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22010145</ArticleId><ArticleId IdType="pmc">PMC7795389</ArticleId><ArticleId IdType="pubmed">33375653</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. (2020) 16:e1009128. 10.1371/journal.ppat.1009128</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009128</ArticleId><ArticleId IdType="pmc">PMC7746263</ArticleId><ArticleId IdType="pubmed">33284859</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrosa MA, Valenzuela R, Garrido-Gil P, Labandeira CM, Navarro G, Franco R. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci. (2021) 135:465&#x2013;81. 10.1042/CS20201511</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20201511</ArticleId><ArticleId IdType="pmc">PMC7851407</ArticleId><ArticleId IdType="pubmed">33479758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ, Johnson EJ. Targeting the bradykinin B1 receptor to reduce pain. Expert Opin Ther Targets. (2007) 11:21&#x2013;35. 10.1517/14728222.11.1.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.11.1.21</ArticleId><ArticleId IdType="pubmed">17150032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacoste B, Tong XK, Lahjouji K, Couture R, Hamel E. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. J Neuroinflammation. (2013) 10:57. 10.1186/1742-2094-10-57</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-57</ArticleId><ArticleId IdType="pmc">PMC3710240</ArticleId><ArticleId IdType="pubmed">23642031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Tan J, Wan L, Chen C, Wu B, Ke X. Increase in blood-brain barrier permeability is modulated by tissue kallikrein via activation of bradykinin B1 and B2 receptor-mediated signaling. J Inflamm Res. (2021) 14:4283&#x2013;97. 10.2147/JIR.S322225</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S322225</ArticleId><ArticleId IdType="pmc">PMC8417820</ArticleId><ArticleId IdType="pubmed">34511968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhr F, Lowry J, Zhang Y, Brovkovych V, Skidgel RA. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides April. (2010) 44:145&#x2013;54. 10.1016/j.npep.2009.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2009.12.004</ArticleId><ArticleId IdType="pmc">PMC2830320</ArticleId><ArticleId IdType="pubmed">20045558</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med NYN. (2022)13:1.10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res. (2020) 21:182. 10.1186/s12931-020-01445-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01445-6</ArticleId><ArticleId IdType="pmc">PMC7359430</ArticleId><ArticleId IdType="pubmed">32664949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acu&#xf1;a JM, Perez-Romero BA, Guerrero-Rodriguez JF. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci 20 Dezember. (2020) 21:E9739. 10.3390/ijms21249739</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21249739</ArticleId><ArticleId IdType="pmc">PMC7767220</ArticleId><ArticleId IdType="pubmed">33419373</ArticleId></ArticleIdList></Reference><Reference><Citation>Leenen FHH. Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension. Am J Hypertens. (2014) 27:1024&#x2013;32. 10.1093/ajh/hpu066</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpu066</ArticleId><ArticleId IdType="pubmed">24742639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukerjee S, Gao H, Xu J, Sato R, Zsombok A, Lazartigues E. ACE2 and ADAM17 interaction regulates the activity of pre-sympathetic neurons. Hypertens Dallas Tex. (2019) 74:1181&#x2013;91. 10.1161/HYPERTENSIONAHA.119.13133</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.13133</ArticleId><ArticleId IdType="pmc">PMC6785402</ArticleId><ArticleId IdType="pubmed">31564162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SG Yu Y, Felder RB. Blood-borne interleukin-1&#x3b2; acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol. (2018) 314:R447&#x2013;58. 10.1152/ajpregu.00211.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00211.2017</ArticleId><ArticleId IdType="pmc">PMC5899248</ArticleId><ArticleId IdType="pubmed">29167166</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Bluemke DA, L&#xfc;scher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. (2022) 43:1157&#x2013;72. 10.1093/eurheartj/ehac031</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac031</ArticleId><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>de Morais SDB, Shanks J, Zucker IH. Integrative physiological aspects of brain RAS in hypertension. Curr Hypertens Rep. (2018) 20:10. 10.1007/s11906-018-0810-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-018-0810-1</ArticleId><ArticleId IdType="pmc">PMC6324839</ArticleId><ArticleId IdType="pubmed">29480460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali A, Singh N, Jaggi AS. Renin&#x2013;angiotensin system in pain: Existing in a double life? J Renin Angiotensin Aldosterone Syst. (2014) 15:329&#x2013;40. 10.1177/1470320313503694</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320313503694</ArticleId><ArticleId IdType="pubmed">25503939</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. (2022) 7:1689. 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Saluja P, Gautam N, Yadala S, Venkata AN. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases. Thromb Res. (2022) 214:115&#x2013;21. 10.1016/j.thromres.2022.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.04.020</ArticleId><ArticleId IdType="pmc">PMC9060716</ArticleId><ArticleId IdType="pubmed">35533526</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallone MG, Falc&#xf3;n AL, Castro HM, Ferraris A, Cantarella RF, Staneloni MI. Thrombotic events following COVID-19 vaccines compared to Influenza vaccines. Eur J Intern Med Mai. (2022) 99:82&#x2013;8. 10.1016/j.ejim.2022.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.03.002</ArticleId><ArticleId IdType="pmc">PMC8904150</ArticleId><ArticleId IdType="pubmed">35288031</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol Januar. (2021) 113:45&#x2013;57. 10.1007/s12185-020-03029-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-020-03029-y</ArticleId><ArticleId IdType="pmc">PMC7648664</ArticleId><ArticleId IdType="pubmed">33161508</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitt AG, Manimala S, White T, Fandaros M, Yin W, Duan H. SARS-CoV-2 exacerbates COVID-19 pathology through activation of the complement and kinin systems. Front Immunol. (2021) 12:767347. 10.3389/fimmu.2021.767347</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.767347</ArticleId><ArticleId IdType="pmc">PMC8602850</ArticleId><ArticleId IdType="pubmed">34804054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. (2022) 12:861703. 10.3389/fcimb.2022.861703</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. (2022) 479:537&#x2013;59. 10.1042/BCJ20220016</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K. American society of hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis. Blood Adv. (2022) 6:664&#x2013;71. 10.1182/bloodadvances.2021005945</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005945</ArticleId><ArticleId IdType="pmc">PMC8566097</ArticleId><ArticleId IdType="pubmed">34727173</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas C, Renn&#xe9; T. Coagulation factor XII in thrombosis and inflammation. Blood. (2018) 131:1903&#x2013;9. 10.1182/blood-2017-04-569111</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-04-569111</ArticleId><ArticleId IdType="pubmed">29483100</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem. (2003) 46:2261&#x2013;70. 10.1021/jm0204237</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0204237</ArticleId><ArticleId IdType="pubmed">12773029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway H, Moore GJ, Mavromoustakos T, Tsiodras S, Ligielli I, Kelaidonis K. Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Comput Struct Biotechnol J. (2022) 20:2091&#x2013;111. 10.1016/j.csbj.2022.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.04.010</ArticleId><ArticleId IdType="pmc">PMC8994259</ArticleId><ArticleId IdType="pubmed">35432786</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A. Telmisartan for treatment of COVID-19 patients: An open multicenter randomized clinical trial. EClin Med. (2021) 37:100962. 10.1016/j.eclinm.2021.100962</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100962</ArticleId><ArticleId IdType="pmc">PMC8225700</ArticleId><ArticleId IdType="pubmed">34189447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZF Li J, Ma C, Huang C, Li ZQ. Telmisartan ameliorates A&#x3b2; oligomer-induced inflammation via PPAR&#x3b3;/PTEN pathway in BV2 microglial cells. Biochem Pharmacol. (2020) 171:113674. 10.1016/j.bcp.2019.113674</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.113674</ArticleId><ArticleId IdType="pubmed">31634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 6. (2017) 120:229&#x2013;43. 10.1161/CIRCRESAHA.116.308537</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.308537</ArticleId><ArticleId IdType="pmc">PMC5467317</ArticleId><ArticleId IdType="pubmed">28057795</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe4;rz W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol Off J Ger Card Soc. (2017) 106:663&#x2013;75. 10.1007/s00392-017-1106-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-017-1106-1</ArticleId><ArticleId IdType="pmc">PMC5565659</ArticleId><ArticleId IdType="pubmed">28342064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorci-Thomas MG, Thomas MJ. Micro-domains, Inflammation, and Atherosclerosis. Circ Res. (2016) 118:679&#x2013;91. 10.1161/CIRCRESAHA.115.306246</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306246</ArticleId><ArticleId IdType="pmc">PMC5291489</ArticleId><ArticleId IdType="pubmed">26892966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. eLife. (2021) 10:e65962. 10.7554/eLife.65962</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65962</ArticleId><ArticleId IdType="pmc">PMC8104966</ArticleId><ArticleId IdType="pubmed">33890572</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-R&#xe1;palo SN, De Jes&#xfa;s-Gonz&#xe1;lez LA, Cordero-Rivera CD, Farfan-Morales CN, Osuna-Ramos JF, Mart&#xed;nez-Mier G. Cholesterol-rich lipid rafts as platforms for SARS-CoV-2 entry. Front Immunol. (2021) 12:796855. 10.3389/fimmu.2021.796855</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.796855</ArticleId><ArticleId IdType="pmc">PMC8719300</ArticleId><ArticleId IdType="pubmed">34975904</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. (2001) 5:378&#x2013;87. 10.1111/j.1582-4934.2001.tb00172.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2001.tb00172.x</ArticleId><ArticleId IdType="pmc">PMC6740083</ArticleId><ArticleId IdType="pubmed">12067471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep 15 Oktober. (2020) 10:17458. 10.1038/s41598-020-74492-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74492-0</ArticleId><ArticleId IdType="pmc">PMC7562925</ArticleId><ArticleId IdType="pubmed">33060704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. (2021) 330:114&#x2013;21. 10.1016/j.atherosclerosis.2021.06.911</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.06.911</ArticleId><ArticleId IdType="pmc">PMC8233054</ArticleId><ArticleId IdType="pubmed">34243953</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira L, Temerozo JR, Pereira-Dutra FS, Ferreira AC, Mattos M, Gon&#xe7;alves BS. Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts. Front Immunol. (2022) 13:820131. 10.3389/fimmu.2022.820131</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.820131</ArticleId><ArticleId IdType="pmc">PMC8895251</ArticleId><ArticleId IdType="pubmed">35251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas F, Tibiri&#xe7;&#xe1; E, Singh M, Fraser PA, Mann GE. Redox regulation of microvascular permeability: IL-1&#x3b2; potentiation of bradykinin-induced permeability is prevented by simvastatin. Antioxid Basel Switz. (2020) 9:E1269. 10.3390/antiox9121269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9121269</ArticleId><ArticleId IdType="pmc">PMC7764912</ArticleId><ArticleId IdType="pubmed">33327440</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R. Long COVID-19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. (2021) 8:745758. 10.3389/fcvm.2021.745758</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol Mai. (2006) 6:358&#x2013;70. 10.1038/nri1839</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1839</ArticleId><ArticleId IdType="pmc">PMC3842637</ArticleId><ArticleId IdType="pubmed">16639429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M. The microbiota-gut-brain axis. Physiol Rev. (2019) 99:1877&#x2013;2013. 10.1152/physrev.00018.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2018</ArticleId><ArticleId IdType="pubmed">31460832</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B. Mast cells and inflammation. Biochim Biophys Acta BBA Mol Basis Dis. (2012) 1822:21&#x2013;33. 10.1016/j.bbadis.2010.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.12.014</ArticleId><ArticleId IdType="pmc">PMC3318920</ArticleId><ArticleId IdType="pubmed">21185371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. (2018) 11:345&#x2013;9. 10.2147/JIR.S174982</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S174982</ArticleId><ArticleId IdType="pmc">PMC6159811</ArticleId><ArticleId IdType="pubmed">30288077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy April. (2022) 77:1288&#x2013;91. 10.1111/all.15188</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15188</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Lizarraga J, Florens MV, Viola MF, Jain P, Decraecker L, Appeltans I. Local immune response to food antigens drives meal-induced abdominal pain. Nature. (2021) 590:151&#x2013;6. 10.1038/s41586-020-03118-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03118-2</ArticleId><ArticleId IdType="pmc">PMC7610810</ArticleId><ArticleId IdType="pubmed">33442055</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology Januar. (2007) 132:26&#x2013;37. 10.1053/j.gastro.2006.11.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2006.11.039</ArticleId><ArticleId IdType="pubmed">17241857</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan S, Leo MD. Histamine potentiates SARS-CoV-2 spike protein entry into endothelial cells. Front Pharmacol 25 April. (2022) 13:872736. 10.3389/fphar.2022.872736</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.872736</ArticleId><ArticleId IdType="pmc">PMC9084361</ArticleId><ArticleId IdType="pubmed">35548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikmet F, M&#xe9;ar L, Edvinsson &#xc5;, Micke P, Uhl&#xe9;n M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol Juli. (2020) 16:e9610. 10.15252/msb.20209610</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20209610</ArticleId><ArticleId IdType="pmc">PMC7383091</ArticleId><ArticleId IdType="pubmed">32715618</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med Januar. (2022) 70:61&#x2013;7. 10.1136/jim-2021-002051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathog Basel Switz 17 Juni. (2021) 10:763. 10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Mese K, Kowallick JT, Schuster A, Tampe D, Tampe B. Case report: cytomegalovirus reactivation and pericarditis following chadox1 ncov-19 vaccination against SARS-CoV-2. Front Immunol. (2021) 12:784145. 10.3389/fimmu.2021.784145</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.784145</ArticleId><ArticleId IdType="pmc">PMC8803643</ArticleId><ArticleId IdType="pubmed">35116025</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>